A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Recruiting · NCT05761223 · Registry updated 2025-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2025-08-17 | NCT05761223 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| 1ST Biotherapeutics, Inc. | 3 |
| Merck Sharp & Dohme LLC | 650 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic | Cleveland | United States | 558 |
| Mary Crowley Cancer Research Center | Dallas | United States | 1 |
| Next Oncology San Antonio | San Antonio | United States | 6 |
| NEXT Oncology Virginia | Fairfax | United States | 40 |
| Summit Cancer Centers - Spokane Valley | Spokane | United States | 1 |